Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 57.00 | |
2 mg | In stock | $ 83.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 263.00 | |
25 mg | In stock | $ 597.00 | |
50 mg | In stock | $ 852.00 | |
100 mg | In stock | $ 1,170.00 | |
500 mg | In stock | $ 2,350.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 153.00 |
Description | Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK). |
In vitro | In both biochemical and cellular assays, BGB-3111 demonstrated nanomolar BTK inhibition activity. In several MCL and DLBCL cell lines, BGB-3111 inhibited BCR aggregation-triggered BTK autophosphorylation, blocked downstream PLC-γ2 signaling, and potently inhibited cell proliferation. In comparison with ibrutinib, BGB-3111 showed much more restricted off-target activities against a panel of kinases, including ITK. While ibrutinib significantly inhibited rituximab-induced NK cell IFN-γ secretion and in vitro cytotoxicity on mantle cell lymphoma cells, BGB-3111 was at least 10-fold weaker than ibrutinib in inhibiting rituximab induced ADCC, consistent with its weak ITK inhibition activity[1]. |
In vivo | In mouse BTK occupancy assays, treatment with BGB-3111 resulted in a dose-dependent BTK occupancy and showed about 3-fold more potency than ibrutinib in target organs, including PBMC and spleen.?BGB-3111 induced dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice.?In the subcutaneous xenografts, BGB-3111 at 2.5 mg/kg BID showed similar activity as ibrutinib at 50 mg/kg QD, its clinical relevant dose.?In the systemic model, the median survival of BGB-3111 25 mg/kg BID group was significantly longer than those of both ibrutinib 50 mg/kg QD and BID groups.?In an ABC-subtype DLBCL (TMD-8) subcutaneous xenograft model, BGB-3111 also demonstrated better anti-tumor activity than ibrutinib.?Preliminary 14-day toxicity study in rats showed that BGB-3111 was very well tolerated and maximal tolerate dose (MTD) was not reached when it was dosed up to 250mg/kg/day[1]. |
Synonyms | BGB-3111 |
Molecular Weight | 471.55 |
Formula | C27H29N5O3 |
CAS No. | 1691249-45-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 56.75 mg/mL (120.35 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
zanubrutinib 1691249-45-2 Angiogenesis Tyrosine Kinase/Adaptors BTK Btk BGB3111 BGB-3111 Inhibitor BGB 3111 inhibit Bruton tyrosine kinase inhibitor